CompaniesTessa Therapeutics

Tessa Therapeutics

defunct
About

Defunct Company

Areas of Focus

Categories

Bankrupt, Merged, Sold, Renamed or Otherwise Defunct
Clinical Trials (4)
View all

Total Trials

4

As Lead Sponsor

4

As Collaborator

0

Total Enrollment

463

By Phase

PHASE1: 2PHASE2: 1PHASE3: 1

By Status

ACTIVE_NOT_RECRUITING: 3COMPLETED: 1
Clinical Trials Pipeline4 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
2032
2033
2034
2035
2036
2037
2038
Today
NCT02578641
NCT04268706
NCT04526834
NCT05352828
Hover over trial bars to see details

Recent Trials

NCT05352828Lead Sponsor
Autologous CD30.CAR-T in Combination With Nivolumab in cHL Patients After Failure of Frontline Therapy
PHASE1Active, not recruiting
15 participants
Started: Jul 25, 2022 · Completed: Dec 15, 2037
NCT04526834Lead Sponsor
Phase 1 Study of Autologous CD30.CAR-T in Relapsed or Refractory CD30 Positive Non-Hodgkin Lymphoma
PHASE1Active, not recruiting
21 participants
Started: Sep 8, 2021 · Completed: Mar 31, 2036
NCT04268706Lead Sponsor
Phase 2 Study Evaluating Autologous CD30.CAR-T Cells in Patients With Relapsed/Refractory Hodgkin Lymphoma (CHARIOT)
PHASE2Active, not recruiting
97 participants
Started: Feb 1, 2021 · Completed: Mar 31, 2037
NCT02578641Lead Sponsor
A Phase III Trial Evaluating Chemotherapy and Immunotherapy for Advanced Nasopharyngeal Carcinoma (NPC) Patients
PHASE3Completed
330 participants
Started: Jul 31, 2014 · Completed: Feb 28, 2022